Most Popular
1. Banking Crisis is Stocks Bull Market Buying Opportunity - Nadeem_Walayat
2.The Crypto Signal for the Precious Metals Market - P_Radomski_CFA
3. One Possible Outcome to a New World Order - Raymond_Matison
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
5. Apple AAPL Stock Trend and Earnings Analysis - Nadeem_Walayat
6.AI, Stocks, and Gold Stocks – Connected After All - P_Radomski_CFA
7.Stock Market CHEAT SHEET - - Nadeem_Walayat
8.US Debt Ceiling Crisis Smoke and Mirrors Circus - Nadeem_Walayat
9.Silver Price May Explode - Avi_Gilburt
10.More US Banks Could Collapse -- A Lot More- EWI
Last 7 days
Stock Market Volatility (VIX) - 25th Mar 24
Stock Market Investor Sentiment - 25th Mar 24
The Federal Reserve Didn't Do Anything But It Had Plenty to Say - 25th Mar 24
Stock Market Breadth - 24th Mar 24
Stock Market Margin Debt Indicator - 24th Mar 24
It’s Easy to Scream Stocks Bubble! - 24th Mar 24
Stocks: What to Make of All This Insider Selling- 24th Mar 24
Money Supply Continues To Fall, Economy Worsens – Investors Don’t Care - 24th Mar 24
Get an Edge in the Crypto Market with Order Flow - 24th Mar 24
US Presidential Election Cycle and Recessions - 18th Mar 24
US Recession Already Happened in 2022! - 18th Mar 24
AI can now remember everything you say - 18th Mar 24
Bitcoin Crypto Mania 2024 - MicroStrategy MSTR Blow off Top! - 14th Mar 24
Bitcoin Gravy Train Trend Forecast 2024 - 11th Mar 24
Gold and the Long-Term Inflation Cycle - 11th Mar 24
Fed’s Next Intertest Rate Move might not align with popular consensus - 11th Mar 24
Two Reasons The Fed Manipulates Interest Rates - 11th Mar 24
US Dollar Trend 2024 - 9th Mar 2024
The Bond Trade and Interest Rates - 9th Mar 2024
Investors Don’t Believe the Gold Rally, Still Prefer General Stocks - 9th Mar 2024
Paper Gold Vs. Real Gold: It's Important to Know the Difference - 9th Mar 2024
Stocks: What This "Record Extreme" Indicator May Be Signaling - 9th Mar 2024
My 3 Favorite Trade Setups - Elliott Wave Course - 9th Mar 2024
Bitcoin Crypto Bubble Mania! - 4th Mar 2024
US Interest Rates - When WIll the Fed Pivot - 1st Mar 2024
S&P Stock Market Real Earnings Yield - 29th Feb 2024
US Unemployment is a Fake Statistic - 29th Feb 2024
U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - 29th Feb 2024
What a Breakdown in Silver Mining Stocks! What an Opportunity! - 29th Feb 2024
Why AI will Soon become SA - Synthetic Intelligence - The Machine Learning Megatrend - 29th Feb 2024
Keep Calm and Carry on Buying Quantum AI Tech Stocks - 19th Feb 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Big Upside in this "Life or Death" Stock Market Sector

Stock-Markets / Healthcare Sector Sep 27, 2009 - 03:43 PM GMT

By: GrowthStockWire

Stock-Markets

The diagnostics industry was once regarded as a red-headed stepchild for medical investors.



Focused on cheap tests for cholesterol and blood sugar, the market quickly became commoditized. Size, scale, and consolidation overran the industry. Anyone with access to low-wage technicians could enter this game.

Things have changed. Diagnostics now does $50 billion in annual business. The technology is increasingly sophisticated. Trained geneticists and molecular biologists run tests with huge price tags. The rewards for early investors can be huge...

Today, I'm most interested in a hidden and ultra-fast-growing subsector of medical testing market: cancer diagnostics. Here, speed and accuracy is critical for life-or-death decisions. And the companies with the best technologies own the market.

Take leukemia diagnostics...

Mutations in more than 50 genes can contribute to or exacerbate the progression of leukemia. Diagnosis is time-consuming and expensive, on average $3,000 per procedure. But identifying the right disease fast is absolutely critical...

Chronic myelogenous leukemia (CML), for example, is a rare blood disorder that springs from a single genetic alteration. Because the disease's early stages come with no symptoms, some CML patients go undiagnosed for months. If caught too late, CML can kill within weeks. But if doctors pick it up early enough, one "miracle drug" – Gleevac – can help CML patients live more than eight years with the disease.

But Gleevec is utterly worthless in other leukemias, including the genetically similar (and equally devastating) acute lymphoblastic leukemia. These patients are limited to chemotherapy, radiation, and bone marrow transplant. An imprecise diagnosis can waste crucial days and weeks.

Today, cancer diagnostics is a $6 billion market. It's growing more than 10% a year. And this growth rate will pick up in the years ahead. Here's why:

Cancer remains one of the leading causes of death worldwide. Roughly 15% of the population gets some form of the disease at some point in their life. In the U.S. alone, more than 1.5 million new cancer diagnoses are made every year.

Hundreds of companies are clamoring for a piece of the growing cancer diagnostics market. Two of my favorites are Genomic Health (GHDX) and Myriad Genetics (MYGN). Each offer testing products for breast cancer.

Myriad sells a screening test for women who come from families with a history of breast cancer. Women pre-disposed to the disease have a chance to pursue preventative medical strategies. Genomic Health's test predicts whether a patient's breast cancer will respond to chemotherapy or not, based on a tumor's molecular "fingerprint."

With the coming growth in the diagnostics industry, both Genomic and Myriad are attractive long-term investments at current prices. These companies have the technology and expertise to dominate their niche. And their products can mean the difference between life and death.

Good investing,

Rob Fannon

http://www.growthstockwire.com

The Growth Stock Wire is a free daily e-letter that provides readers with a pre-market briefing on the most profitable opportunities in the global stock, currency, and commodity markets. Written by veteran trader Jeff Clark, and featuring expert guest commentaries, Growth Stock Wire is delivered to your inbox each weekday morning before the markets open.

Customer Service: 1-888-261-2693 – Copyright 2009 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

Growth Stock Wire Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in